

HENDRICH II FALL RISK MODEL®

RISK FACTOR		RISK POINTS	SCORE
Confusion/Disorientation/Impulsivity		4	
Symptomatic Depression		2	
Altered Elimination		1	
Dizziness/Vertigo		1	
Gender (Male)		1	
Any Administered Antiepileptics (Anticonvulsants) ¹	Carbamazepine, Divalproex Sodium, Ethotoin, Ethosuximide, Felbamate, Fosphenytoin, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam, Methsuximide, Oxcarbazepine, Phenobarbital, Phenytoin, Pregabalin, Primidone, Topiramate, Trimethadione, Valproic Acid, Zonisamide	2	
Any Administered Benzodiazepines ²	Alprazolam, Chlordiazepoxide, Clobazam, Clonazepam, Lorazepam, Diazepam, Estazolam, Eszopiclone, Flurazepam, Halazepam, Lorazepam, Midazolam, Oxazepam, Quazepam, Ramelteon, Temazepam, Triazolam, Zaleplon, Zolpidem	1	
Get-Up-and-Go Test: “Rising From a Chair” NOTE: If unable to assess, monitor for change in activity level, assess other risk factors, document both on patient chart with date and time.			
Ability to rise in a single movement - no loss of balance with steps		0	
Pushes up, successful in one attempt		1	
Multiple attempts, but successful		3	
Unable to rise without assistance during test		4	
A TOTAL SCORE OF 5 OR GREATER = HIGH RISK		TOTAL SCORE:	

©2020, AHI of Indiana Inc. All Rights Reserved. United States Patent Nos. 7,282,031 and 7,682,308. Federal laws prohibit the replication, distribution or clinical use expressed or implied without written permission from AHI of Indiana, Incorporated.

ONGOING MEDICATION REVIEW UPDATES:

¹ Keppra (levetiracetam) was not assessed during the original research conducted to create the Hendrich Fall Risk Model. As an antiepileptic, levetiracetam does have a side effect of somnolence and dizziness which contributes to its fall risk and should be scored (June 2010, June 2020). Banzel (rufinamide), Sabril (vigabatrin), Gabitril (tiagabine) were not included in the study and are not commonly seen in practice, however, they are currently available and could be seen on patient medication lists (September 2018). Vimpat (lacosamide), Trileptal (oxcarbazepine), Lyrica (pregabalin) and Zonegran (zonisamide) are not included in the list above because they were not assessed during the original Hendrich research but were included in the 2020 validation study. These medications can cause documented CNS effects and should be scored if administered (February 2019, June 2020). Mesantoin (mephenytoin) was included in the study but is no longer available in the United States (November 2020).

² The study did not include the effect of benzodiazepine-like drugs since they were not on the market at the time. However, due to their similarity in drug structure, mechanism of action and drug effects, they should also be scored. They are Lunesta (eszopiclone), Rozerem (ramelteon), Sonata (zaleplon), and Ambien, Intermezza (zolpidem). (June 2010, February 2019, June 2020). Prosom (Estazolam), Doral (Quazepam), Onfi (Clobazam) were not included in the study and are not commonly seen in practice, however, they are currently available and could be seen on patient medication lists (September 2018, June 2020).

³ Halazepam was included in the study but is no longer available in the United States. (June 2010)